Q4 2025 Bioventus Inc Earnings Call Transcript
Key Points
- Bioventus Inc (BVS) delivered 10% organic revenue growth in the fourth quarter, driven by strong performance across core businesses.
- The company achieved a record for quarterly cash from operations at approximately $38 million, aided by improved inventory management.
- Bioventus Inc (BVS) expanded its adjusted EBITDA margin by almost 500 basis points compared to the prior year.
- The company successfully launched pilot programs for growth drivers like peripheral nerve stimulation (PNS) and platelet-rich plasma (PRP), receiving positive market feedback.
- Bioventus Inc (BVS) refinanced its term loan, enhancing liquidity and reducing interest expenses, which is expected to continue benefiting the company in 2026.
- Foreign exchange rates had an unfavorable impact on the fourth quarter, resulting in an unplanned loss of almost $1 million.
- Revenue from the Surgical Solutions segment grew only 3% due to tough comparisons with the prior year's capital sales.
- The Restorative Therapies segment saw a 26% revenue decline compared to the prior year due to the divestiture of the Advanced Rehabilitation business.
- The company anticipates lower growth in the first quarter of 2026 due to one fewer selling day and rebalancing of HA distributor inventory levels.
- Bioventus Inc (BVS) faces challenges in maintaining the same level of organic growth in the HA business as seen in 2025, partly due to selling days and inventory normalization.
Good day, and welcome to the Bioventus fourth-quarter 2025 earnings conference call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Mr. Dave Crawford. Please go ahead.
Thanks, Chuck, and good morning, everyone. Thanks for joining us. It's my pleasure to welcome you to the Bioventus 2025 fourth-quarter earnings conference call. With me this morning are Rob Claypoole, President and CEO; and Mark Singleton, Senior Vice President and CFO. Rob will begin his remarks with an update on our business, review our performance against our 2025 priorities, and lay out our 2026 objectives. Then Mark will review the fourth quarter results and discuss our 2026 financial guidance. We will finish the call with Q&A.
A presentation for today's call is available on the investors section of our website, bioventus.com. Before we begin, I would like to remind everyone that our remarks today contain forward-looking statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
